Acer Therapeutics (Acer Therapeutics) Cash Conversion Cycle : 0.00 (As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Acer Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2023 was 0.
Acer Therapeutics's Days Inventory for the three months ended in Jun. 2023 was 0.
Acer Therapeutics's Days Payable for the three months ended in Jun. 2023 was 0.
Therefore, Acer Therapeutics's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2023 was 0.00.

Acer Therapeutics Cash Conversion Cycle Historical Data

The historical data trend for Acer Therapeutics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics Cash Conversion Cycle Chart

Acer Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash Conversion Cycle

Get a 7-Day Free Trial

1,448.41

Acer Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash Conversion Cycle	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Acer Therapeutics's Cash Conversion Cycle

For the Biotechnology subindustry, Acer Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acer Therapeutics's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acer Therapeutics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Acer Therapeutics's Cash Conversion Cycle falls into.

Acer Therapeutics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Acer Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Acer Therapeutics's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Acer Therapeutics (OTCPK:ACER) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Acer Therapeutics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Acer Therapeutics (Acer Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458

Website

https://www.acertx.com

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Executives

Chris Schelling	director, officer: President and Chief Executive	C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden	officer: Chief Operating Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel	officer: Chief Medical Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul	officer: Chief People Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis	officer: Chief Business Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph	officer: Chief Legal Officer and Secy	C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp	officer: Chief Technology Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin	officer: Chief Opp. and Financial Offr	C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello	director	500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458